A Phase 3 study in The New England Journal of Medicine found that tirzepatide was associated with lower risk of progression to type 2 diabetes among adults with prediabetes and obesity or overweight.
Almost 99 per cent of people remained diabetes-free after the 176-week treatment period, and 2.4 per cent were diagnosed with diabetes after a 17-week follow-up period.
These results have suggested that one new case of diabetes could be prevented for every nine individuals treated with tirzepatide.
More than 1,000 adults took part in the trial, all of whom had prediabetes. The participants either received three doses of tirzepatide or placebo.
A 15 mg dose of tirzepatide can push people to lose roughly 22.9 per cent of their body weight. This is compared to just 2.1 per cent of weight loss among those in the trial’s control arm.
Meanwhile, individuals on the 5-mg and 10-mg doses of tirzepatide saw their weight drop by 15.4 per cent and 19.9 per cent.
Dr Jeff Emmick, Senior Vice President of Product Development at Lilly, said: “These results underscore the critical role of long-term therapy with effective treatments like tirzepatide to achieve and maintain weight reduction.”
Previous research has found that tirzepatide is associated with a reduced risk of adverse heart failure outcomes by 38 per cent.
The full study can be accessed here.
Customer Reviews
Thanks for submitting your comment!